Cognitive Enhancement Research Dihexa Dihexa has been directly tested in cognitive paradigms (aged rat water maze, scopolamine reversal) and demonstrates synaptogenesis through HGF/c-Met signaling, providing a more direct cognitive enhancement rationale than PE-22-28 Neurogenesis and Mood Research PE-22-28 PE-22-28 induces hippocampal neurogenesis within 4 days and demonstrates antidepressant-like effects through TREK-1 blockade, making it more relevant for mood-cognition intersection research Oral Bioavailability Requirement Dihexa Dihexa has demonstrated approximately 38% oral bioavailability with BBB penetration, while PE-22-28 oral availability has not been characterized Lower Theoretical Risk Profile PE-22-28 PE-22-28 targets an ion channel without known oncological associations, whereas Dihexa activates the HGF/c-Met pathway which is a characterized oncogenic signaling axis Evidence Reliability PE-22-28 PE-22-28 has no retracted publications in its evidence base, while a key 2014 Dihexa paper was retracted for data fabrication concerns Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly
Sources Chemo Relay (1.0) Chemo Relay (1.0, beta) Beta: served but experimental, data-limited and below our cross-validation release bar
10.1016/j.mcn.2012.03.005 57 KwonM.FernandezJ
Angiogenesis & recovery Researched in animal models for new blood-vessel formation thought to support recovery
1:303:00 pm CDT Efficacy and Safety of CagriSema 2.4mg/2.4mg in Adults with Overweight/ObesityThe REDEFINE 1 and REDEFINE 2 Clinical Trials Sunday, June 22
Cagrilintide acts on amylin and calcitonin receptors, while semaglutide is a GLP-1 receptor agonist
